WO2010135574A2 - Systems and methods for determining the percentage of glycated hemoglobin - Google Patents
Systems and methods for determining the percentage of glycated hemoglobin Download PDFInfo
- Publication number
- WO2010135574A2 WO2010135574A2 PCT/US2010/035648 US2010035648W WO2010135574A2 WO 2010135574 A2 WO2010135574 A2 WO 2010135574A2 US 2010035648 W US2010035648 W US 2010035648W WO 2010135574 A2 WO2010135574 A2 WO 2010135574A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- detectable marker
- hemoglobin
- sample
- labeled
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
- G01N33/526—Multi-layer analytical elements the element being adapted for a specific analyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- Diabetes mellitus is a chronic disorder characterized by insulin deficiency, hyperglycemia, and high risk for development of complications of the eyes, kidneys, peripheral nerves, heart and blood vessels.
- the disease is highly prevalent, affecting as many as 16 million people in the U.S.
- the disease is also expensive, in terms of both human suffering and dollars; it is estimated that approximately 1 in every 7 health care dollars spent in the U.S. goes to diabetes care, mostly for treatment of the chronic complications.
- diabetes is the most common cause of blindness in young adults, kidney failure, and non-traumatic limb amputation.
- the Diabetes Control and Complications Trial completed in 1993, showed that the risk for development and progression of the chronic complications of diabetes is closely related to the degree of glycemic control, as measured by glycated hemoglobin (GHb) determinations.
- the DCCT also provided a large body of data relating GHb values to mean blood glucose.
- the DCCT results have set the stage for establishing specific diabetes treatment goals using GHb as an index of mean blood glucose concentration.
- POC point-of- care
- POC diagnostic assays and related devices have been developed for point-of- care (POC) testing.
- POC diagnostic assays and related devices In view of the convenience of POC diagnostic assays and related devices, the timeliness of their results, and the high incidence of diabetes, the need for an early diagnostic test for discovery of predilection to diabetes, and also for monitoring therapy has emphasized the extraordinary need for a POC diagnostic test. This is best accommodated in non hospital environments and also in situations where phlebotomists are not required (i. e. , there is no need for blood draws).
- POC devices may be portable or otherwise transportable. In some cases, they may even be handheld.
- the present invention describes a method of determining blood glucose levels by measuring the amount of glycated hemoglobin in a small sample of blood making use of chromatographic test strips in an assay system that is amenable to POC device configuration.
- the present invention is based, in part, on the discovery of methodologies for the quantitative analysis of hemoglobin (Hb), glycated hemoglobin (GHb), and other variants to be tested. Accordingly the present invention provides systems for performing the assays and methods for determining the amount of glycated hemoglobin in a blood sample.
- the systems and methods described here may be used in point-of-care (POC) testing, with devices that may be portable and even handheld, and in some cases may be battery-operated.
- the methodologies described here may be CLIA- waived (where "CLIA" refers to Clinical Laboratory Improvement Amendments).
- glycated hemoglobin coupled to both an antibody that recognizes hemoglobin, labeled with a first detectable marker, and to a boronic acid, or a derivative thereof, labeled with a second detectable marker.
- the method comprises detecting a first detectable marker coupled to a first agent that binds hemoglobin in the sample and a second detectable marker coupled to a second agentthat binds only glycated hemoglobin in the sample and determining the percentage of glycated hemoglobin in the sample based on the amount of the first detectable marker and the second detectable marker Attorney Docket No.: RLA0007-401 PC
- the signals from the first detectable marker and the second detectable marker may, optionally, be measured simultaneously.
- the method comprises detecting a first detectable marker coupled to a first agent that binds hemoglobin in the sample and a second detectable marker coupled to a second agent, a boronic acid or a derivative thereof, that binds only glycated hemoglobin in the sample and determining the percentage of glycated hemoglobin in the sample based on the amount of the first detectable marker and the second detectable marker detected in the sample.
- the signals from the first detectable marker and the second detectable marker may, optionally, be measured simultaneously.
- the method comprises the steps of contacting the hemoglobin released from cells in a sample with a first agent, labeled with a first detectable marker, that binds hemoglobin and with a second agent that is labeled with a second detectable marker, that binds only glycated hemoglobin; immobilizing the detectably labeled hemoglobin on a solid support; measuring signals from the first detectable marker and the second detectable marker immobilized on the solid support; and determining the percentage of glycated hemoglobin in the sample based on the signals from the first detectable marker and the second detectable marker.
- the signals from the first detectable marker and the second detectable marker may, optionally, be measured simultaneously.
- the method comprises the steps of contacting the hemoglobin released from cells in a sample with a first agent, labeled with a first detectable marker, that binds hemoglobin and with a second agent, a boronic acid or a derivative thereof, that is labeled with a second detectable marker, that binds only glycated hemoglobin; immobilizing the detectably labeled hemoglobin on a solid support; measuring signals from the first detectable marker and the second detectable marker immobilized on the solid support; and determining the percentage of glycated hemoglobin in the sample based on the signals from the first detectable marker and the second detectable marker.
- signals from the first detectable marker and the second detectable marker are measured simultaneously.
- the method comprises the steps of contacting the hemoglobin released from cells in a sample with a first agent, labeled with a first detectable marker, that binds hemoglobin and with a second agent that is labeled with a second detectable marker, that binds only glycated hemoglobin; immobilizing the detectably labeled Attorney Docket No.: RLA0007-401 PC
- hemoglobin including the detectably labeled glycated hemoglobin, at the same region on a solid support; simultaneously measuring signals from the first detectable marker and the second detectable marker immobilized on the solid support; and determining the percentage of glycated hemoglobin in the sample based on the signals from the first detectable marker and the second detectable marker.
- the first detectable marker is a first fluorophore that fluoresces upon exposure to light of a first wavelength and the second detectable marker is a second fluorophore that fluoresces upon exposure to light of a second wavelength and the signals from the first detectable marker and the second detectable marker immobilized on the solid support are measured by exposing the region of the solid support to which hemoglobin, including glycated hemoglobin, is immobilized to light of the first and second wavelengths.
- the invention provides a system for quantitatively determining the percentage of glycated hemoglobin in a blood sample.
- the invention provides a test strip for quantitatively determining the percentage of glycated hemoglobin in a blood sample.
- the test strip comprises a chromatographic strip; a coating on a portion of the chromatographic strip that comprises a capture agent that binds to hemoglobin in a sample; a region on the chromatographic strip to which sample is added; and a region on the chromatographic strip that comprises a first agent, labeled with a first detectable marker, that binds hemoglobin, and a second agent, labeled with a second detectable marker, that binds only glycated hemoglobin, wherein the region on the chromatographic strip that comprises the first agent and the second agent is located (i) at the region to which the sample is added or (ii) in between the region to which the sample is added and the region comprising the capture agent such that sample that is added to the test strip flows across the region comprising the first and second agents before reaching the region comprising the capture agent.
- the first detectable marker is a fluorophore that fluoresces upon exposure to light of a first wavelength and the second detectable marker is a fluorophore that fluoresces upon exposure to light of a second wavelength.
- the first and second detectable markers are detected simultaneously.
- the test strip comprises a chromatographic strip; a coating on a portion of the chromatographic strip that comprises a capture agent that binds to hemoglobin in a sample; a region on the chromatographic strip to which sample is added; and a region on the chromatographic strip that comprises a first agent, labeled with a first detectable marker, that binds hemoglobin, and a second agent comprising a boronic acid or a derivative thereof, labeled with a second detectable marker, that binds only glycated Attorney Docket No.: RLA0007-401 PC
- hemoglobin wherein the region on the chromatographic strip that comprises the first agent and the second agent is located (i) at the region to which the sample is added or (ii) in between the region to which the sample is added and the region comprising the capture agent such that sample that is added to the test strip flows across the region comprising the first and second agents before reaching the region comprising the capture agent.
- Figure 1 shows an exemplary flow diagram for determination of % HbAIc in a blood sample.
- the blood sample is lysed to release Hb from red blood cells.
- the released Hb is contacted with an antibody, detectably labeled with a first fluorophore, that binds Hb (fll-Abl) and a boronic acid derivative, BD, detectably labeled with a second fluorophore, that binds only glycated Hb (fl2-BD).
- the labeled Hb and glycated Hb are exposed to predetermined wavelengths of light directed to the first and second fluorophores, respectively, to induce fluorescence.
- the percent of glycated Hb is determined based on the fluorescence from the first and second fluorophores.
- FIG. 2 shows a schematic for determination of glycated Hb in a blood sample according to one embodiment of the invention.
- the blood sample is exposed to a lysis solution to liberate the Hb from the red blood cells.
- the lysed sample is added to a chromatographic strip that comprises an antibody, detectably labeled with a first fluorophore, that binds Hb (fll-Abl) and a boronic acid derivative, 3-aminophenylboronic acid (PB) detectably labeled with a second fluorophore, that binds only glycated Hb (fl2-PB).
- a chromatographic strip that comprises an antibody, detectably labeled with a first fluorophore, that binds Hb (fll-Abl) and a boronic acid derivative, 3-aminophenylboronic acid (PB) detectably labeled with a second fluorophore, that binds only glycated Hb (fl2-PB
- Hemoglobin from the sample binds the antibody labeled with the first fluorophore and glycated hemoglobin from the sample binds the boronic acid derivative, detectably labeled with the second fluorophore.
- the labeled hemoglobin flows along the chromatographic strip to a capture zone, detection area or "test band" comprising an anti-Hb antibody that binds to (and thus captures or immobilizes) hemoglobin.
- the chromatographic strip is exposed to light of 635 nm and 800 nm wavelengths to induce fluorescence from the first and second fluorophores.
- the percent of glycated Hb is determined based on the fluorescence from the first and second fluorophore.
- FIG. 3 shows an alternative schematic for determination of glycated Hb in a blood sample according to another embodiment of the invention.
- the blood sample is exposed to a lysis solution to liberate the Hb from the red blood cells.
- the lysis solution comprises an antibody, detectably labeled with a first fluorophore, that binds Hb (fll-Abl) Attorney Docket No.: RLA0007-401 PC
- PB 3-aminophenylboronic acid
- Hemoglobin from the sample binds the antibody labeled with the first fluorophore and glycated hemoglobin from the sample binds the boronic acid derivative, detectably labeled with the second fluorophore.
- the labeled hemoglobin is added to a chromatographic strip and flows along the chromatographic strip to a capture zone, detection area or "test band" comprising an anti-Hb antibody that binds to (and thus captures or immobilizes) hemoglobin.
- the signals from the first detectable marker and the second detectable marker immobilized on the chromatographic strip are measured.
- the percent of glycated Hb is determined based on the signals from the first and second fluorophore.
- Figure 4 shows exemplary boronic acid derivatives that can be coupled with a detectable marker to make a detectably labeled agent that binds glycated Hb.
- Figure 5a shows the conjugation of a boronic acid containing amine residue at 3' position to a fluorophore, DY-782.
- Figure 5b shows the conjugation of a boronic acid containing sulfhydryl residue at 3' position to a fluorophore, DY-636.
- Figure 6 shows the direct conversion or replacement of the carboxylic acid of a fluorophore with a boronic acid group without the use of an amine or a sulfhydryl group.
- FIG. 7 shows a schematic for an exemplary test strip of the invention.
- the test strip depicted is a bidirectional lateral flow test strip wherein fluid added at Port I located at or near End 1 flows towards End 2 and fluid added at Port II located at or near End 2 flows towards End 1.
- sample is added at Port I and flows towards the reaction regions or capture zones, or detection areas comprising a "test band” and two "control bands.”
- the test band comprises a capture agent that binds to (and thus captures or immobilizes) the analyte in the sample, for example the test band may comprise anti-Hb antibody that binds to hemoglobin.
- control bands "high control” and “low control” comprise a capture agent that binds to, and thus capture, a control present in the sample.
- the test strips of the invention may comprise none, one or more than two control bands.
- Fluid such as additional sample or buffer, e.g., wash buffer may optionally be added at Port II as shown.
- Described herein are systems and methods for assaying a blood sample to quantitatively determine the percentage of glycated hemoglobin in the blood sample.
- the methods and systems described here may be used in a point-of-care (POC) device as well as other in vitro diagnostic (IVD) devices, as appropriate.
- POC point-of-care
- IVD in vitro diagnostic
- the POC systems are designed for on-site testing by non-technical personnel and may be CLIA waived.
- the methods and systems described here may be used in devices that are relatively inexpensive to manufacture, and thus may be made widely available.
- POC devices may be used in devices, such as POC devices, that can provide quantitative analysis of the blood samples in a relatively short period of time (e.g., 60 minutes or less, 50 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, or five to ten minutes, from the time of taking the sample).
- POC devices can provide quantitative analysis of the blood samples in a relatively short period of time (e.g., 60 minutes or less, 50 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, or five to ten minutes, from the time of taking the sample).
- the systems and assay methods described herein can be used with devices such as those described in U.S. Patent Application Serial No. 12/760,518, filed on April 14, 2010 and entitled “Diagnostic Devices and Related Methods," which is incorporated herein by reference in its entirety.
- Hemoglobin is the oxygen-carrying pigment that gives blood its red color and also the predominant protein in red blood cells. About 90% of hemoglobin is hemoglobin A (the “A” stands for adult type). Although one chemical component accounts for 92% of hemoglobin A, approximately 8% of hemoglobin A is made up of minor components that are chemically slightly different. These minor components include hemoglobin AIc, Alb, Alal, and Ala2. Hemoglobin AIc (HbAIc) is a minor component of hemoglobin to which glucose is bound. HbAIc also is referred to as glycosylated hemoglobin, glucosylated hemoglobin or glycated hemoglobin (GHb). These terms for GHb are used interchangeably herein.
- hemoglobin refers to all components of hemoglobin or “total” hemoglobin, including glycated hemoglobin. Accordingly an agent that binds, captures or immobilizes hemoglobin also binds, captures or immobilizes glycated hemoglobin.
- the invention provides a method for determining the percentage of glycated hemoglobin in a sample.
- the method comprises detecting a first detectable marker coupled to a first agent that binds hemoglobin in the sample and detecting a second detectable marker coupled to a second agent that binds only Attorney Docket No.: RLA0007-401 PC
- the percentage of glycated hemoglobin in the sample can be determined based on the amount of the first detectable marker and the second detectable marker detected in the sample.
- the sample can be any fluid that comprises hemoglobin.
- the sample is a blood sample, i.e., a drop or other required quantity of blood.
- the sample comprises cells, e.g., red blood cells ("RBCs"), containing hemoglobin isolated from blood. The cells may, but need not be lysed or made permeable to release the hemoglobin.
- RBCs red blood cells
- the sample is a blood sample or a sample comprising cells containing hemoglobin isolated from blood and the blood or the blood cells are lysed or made permeable in order to release hemoglobin from the cells.
- the sample can be contacted with a lysing agent or agents that make the cells permeable for sufficient time to release the hemoglobin. Any other lysing means or means to make permeable known to one of skill in the art may be also used.
- a lysis buffer may be used.
- the blood sample may be lysed by in a 4mM phosphate buffer, pH 7.5, 1% Triton X-100, 15OmM NaCl, for 1-2 minutes, or other lysis buffers known to one of skill in the art.
- mechanical means for example, high-energy ultrasound (or "sonnication" may be used.
- the lysed sample comprising hemoglobin released from the RBCs can then be contacted with the first agent, labeled with a first detectable marker, that binds hemoglobin and a second agent, labeled with a second detectable marker, that binds only the glycated hemoglobin ("GHb") fraction of hemoglobin.
- the first agent binds hemoglobin forming a first detectable complex.
- the second agent binds GHb.
- glycated hemoglobin has two (2) labels, one from the agent that binds hemoglobin and one from the agent that is specific for glycated hemoglobin.
- the first detectable marker and the second detectable marker can be detected and the percentage of glycated hemoglobin in the sample can be determined based on the amount of the first detectable marker and the second detectable marker detected in the sample.
- any first agent that is not bound to hemoglobin and any second agent not bound to glycated hemoglobin is separated from the first agent and the second agent that is bound to hemoglobin and glycated hemoglobin, respectively, before the first and second detectable markers are detected.
- separation can be performed by any means Attorney Docket No.: RLA0007-401 PC
- electrophoresis e.g., gel or capillary electrophoresis, or by immobilizing the hemoglobin.
- the hemoglobin released from cells in a blood sample is contacted with a first agent, labeled with a first detectable marker, that binds hemoglobin and with a second agent, boronic acid or a derivative thereof, that is labeled with a second detectable marker, that binds only glycated hemoglobin.
- the detectably labeled hemoglobin, including the detectably labeled glycated hemoglobin is then localized in a detection area from which signals from the first and second detectable markers are measured.
- the hemoglobin, including the glycated hemoglobin is localized in the same detection area from which signals from the first and second detectable markers are measured.
- the glycated hemoglobin is localized in a detection area, e.g., a first detection area, from which signals from the first and second detectable markers are measured and unglycated hemoglobin is localized in a different detection area, e.g., a second detection area, from which the signal from only the first detectable marker is measured.
- the detectably labeled hemoglobin can be immobilized on a solid support.
- Any solid support to which a protein can be immobilized can be used to immobilize the detectably labeled hemoglobin.
- Exemplary solid supports include, but are not limited to, a chromatographic strip, e.g., a lateral flow test strip, a dipstick, a microfluidic device, glass or plastic beads, plates or columns, magnetic beads with, or without, a glass or plastic coating etc.
- Other solid supports, known to one of skill in the art can also be used to immobilize the detectably labeled hemoglobin.
- the solid support is a chromatographic strip, e.g., a lateral flow test strip, or a dipstick.
- the solid support is a microfluidic device, a multi-well plastic plate used in ELISA assays, or a microcapillary system.
- the solid support may, but need not, comprise an immobilized capture agent that binds to, and thereby immobilizes the hemoglobin.
- the capture agent is immobilized on the support prior to contacting the sample or detectably labeled hemoglobin with the solid support.
- the capture agent can be added to the sample (or present in a fluid, e.g., lysis buffer to which sample is added) before the sample is added to the solid support.
- the capture agent binds hemoglobin in the sample or other fluid to Attorney Docket No.: RLA0007-401 PC
- capture agent refers to a moiety (or composition) that can be immobilized on a solid support and that recognizes and binds hemoglobin in the sample, such that when it binds the hemoglobin, the hemoglobin is "captured" on the solid support.
- the signals from the first detectable marker bound to hemoglobin and the second detectable marker bound to glycated hemoglobin can be measured by any means known to one of skill in the art.
- the signals from the first and second detectable markers can, but need not, be measured simultaneously. It is appreciated that when Hb, including GHb are immobilized on a solid support, only the signals from the detectably labeled agents bound or immobilized on the solid support, and not those free in solution are measured. In some embodiments, a wash step may be needed to eliminate any unbound detectably labeled agents. Means for ensuring that only the signals from the detectably labeled agents bound to hemoglobin and glycated hemoglobin are measured in those embodiments that use other separation techniques disclosed above will be apparent to one of skill in the art.
- the percentage of glycated hemoglobin in the blood sample can be determined based on the signals from the first detectable marker and the second detectable marker. Further, the diabetic index may be determined according to the National Glycohemoglobin Standardization Program (NGSP).
- NGSP National Glycohemoglobin Standardization Program
- the methods of the invention can be used with any system, as described above, that can be configured to quantitatively determine the percentage of glycated hemoglobin in a sample, the methods discussed herein are with reference to an exemplary system, a test strip comprising a chromatographic strip.
- hemoglobin released from cells in a sample is contacted with the first agent, labeled with the first detectable marker, that binds hemoglobin, and the second agent, labeled with the second detectable marker, that binds only glycated hemoglobin, before the sample is added to the chromatographic strip.
- the cells in the sample may be lysed by contacting the sample with a lysis solution.
- the first and second detectably labeled agents may, for example be present in the lysis solution, such that the Hb, once released from the lysed RBCs, is in contact with the first and second detectably labeled agents.
- the sample is first subject to lysis and the lysed sample is subsequently contacted with the first and second detectably labeled agents. After the first and second detectably labeled agents have bound the hemoglobin and glycated hemoglobin, respectively, the sample is added to the chromatographic strip, where the hemoglobin (including the glycated hemoglobin) is immobilized by the capture agent and quantitatively detected.
- the lysed sample is added to the chromatographic strip without prior contact with the first and second detectably labeled agents.
- the first and second detectably labeled agents are provided on the chromatographic strip at, or near, the point at which the lysed sample is added to the chromatographic strip such that the Hb and GHb in the lysed sample interact with the first and second detectably labeled agents on the chromatographic strip before flowing across the chromatographic strip to the portion comprising the capture agent.
- Exemplary capture agents include, but are not limited to, an antibody, an antibody fragment, an antigen, a peptide, a hapten, or an engineered protein.
- the capture agent is an antibody that recognizes and binds to Hb.
- the capture agent may be a monoclonal antibody or a polyclonal antibody, e.g., a polyclonal antibody recognizing common epitopes present in all hemoglobin molecules such as A, A2, F, C, D, E and S.
- the capture agent can comprise a mixture of antibodies specific for each variant.
- capture agents include antibody fragments such as Fab, F(ab)2, nanobodies, diabodies, aptamers, adnectins, anticalins or a variety of other Hb-specific binding molecules derived by a variety of processes including DARPins and DARTs.
- the first and second agents that binds hemoglobin and glycated hemoglobin respectively can be any moiety or composition that bind hemoglobin and glycated hemoglobin respectively, and can be detectably labeled.
- the first and second agents are an antibody or an antibody fragment, as discussed above. They may be a monoclonal antibodies or a polyclonal antibodies. It is noted that although the capture agent and the first agent both bind Hb, they neither bind the same epitope on Hb, nor do they compete with each other for binding to Hb.
- the second agent that binds glycated hemoglobin is a boronic acid [RB(OH) 2 ] or a derivative thereof. Any derivative of boronic acid now known, or later discovered, that specifically binds GHb can be used.
- the boronic acid derivative Attorney Docket No.: RLA0007-401 PC
- the second agent may, for example, be a phenyl boronate.
- boronic acid derivatives include, but are not limited to, 3-aminophenyl boronic acid, 4-amino-3-nitrophenylboronic acid, or 3-, or 4-sulfydryl (or mercapto) phenylboronic acid as well as those listed in Table 1 below.
- Chemical structures of exemplary boronic acid derivatives that can be used as the second agent for specifically binding GHb are shown in Figure 4.
- the first and second detectable markers attached to the first and second agents, respectively, may be selected from a wide variety of materials.
- the first and second detectable markers are detected simultaneously or from the same region of, e.g., a solid support, it is appreciated that the first detectable marker is either different from the second detectable marker or at least, that the markers can be differentiated when detected.
- detectable markers include, but are not limited to particles, luminescent labels; calorimetric labels, fluorescent labels; chemical labels; enzymes; radioactive labels; or radio frequency labels; metal colloids; and chemiluminescent labels.
- Detection methods based on absorption, change (or a lack of change) in color optical methods, such as measuring light scattering, fluorescence, reflectance, luminescence (e.g., chemiluminescence), or electrical conductivity or capacitance, radioactivity (measured with a Geiger counter, etc.), electrochemical detection of released electroactive agents, such as indium, bismuth, gallium or tellurium ions, as described by Hayes et al. (Analytical Chem. 66:1860-1865 (1994)) or ferrocyanide as suggested by Roberts and Durst (Analytical Chem. 67:482-491 (1995)) may be employed. Other methods may also be used, as appropriate. Moreover, a single detection method may be used, or multiple (e.g., two, three) different detection methods may be used together.
- optical methods such as measuring light scattering, fluorescence, reflectance, luminescence (e.g., chemiluminescence), or electrical conductivity or
- signals from the first detectable marker and/or the second detectable marker are measured by applying light from a first light source and/or a second light source to that region of the chromatographic strip where the total hemoglobin is immobilized.
- a first light source and/or a second light source may comprise lasers. It is appreciated that the light sources can be of fixed or adjustable wavelengths and can be calibrated to deliver the frequency of light needed for optimum illumination of the first detectable marker and the second detectable marker.
- the first or second detectably labeled agent can be exposed to red or infra-red light to induce fluorescence from the first and second detectable markers.
- the first or the second detectable markers may be a fluorophore which fluoresces at a wavelength that differs from that at which heme naturally fluoresces.
- the first and the second detectable markers may be fluorophores which fluoresce at different wavelengths, and which are both different from that at which heme naturally fluoresces.
- the signals from the first detectable marker and the second detectable marker are measured simultaneously.
- the first and the second detectable markers that are detected simultaneously may be fluorophores which Attorney Docket No.: RLA0007-401 PC
- the first and the second detectable markers can be simultaneously exposed to red or infra-red light to induce fluorescence from the first and second detectable markers.
- fluorophores examples include, but are not limited to, Dyomics, Dy-636 or Anaspec, HiLytePlus 647, both of which fluoresce at about 635 nm, or Dyomics, Dy-782 or Pierce, DyLight 800, both of which fluoresce at about 800 nm.
- Methods for the detection of two (or more) different detectable markers, e.g., fluorophores, as well as systems/devices that can be used for the detection are further described in U.S. Patent Application Serial No. 12/760,518, filed on April 14, 2010 and entitled “Diagnostic Devices and Related Methods,” which was previously incorporated herein by reference in its entirety.
- Figures 5a, 5b and 6 show exemplary reactions for the conjugation of a fluorophore to a boronic acid derivative that binds GHb.
- boronic acid containing an amine residue at 3' position (3-aminophenyl boronic acid) or at 4' position (4-Amino-3- nitrophenylboronic acid) can be conjugated to a fluorophore (e.g., DY-782) to form a fluorophore-boronic acid derivative conjugate with an amide link.
- a fluorophore e.g., DY-782
- Figure 5b shows the conjugation of a boronic acid containing a sulfhydryl residue at 3' or 4' position (e.g., 3-mercaptophenyl boronic acid or 4-mercaptophenylboronic acid) to a fluorophore (e.g., DY-636).
- Figure 6 shows the direct conversion or replacement of the carboxylic acid of a fluorophore with a boronic acid group without the use of an amine or a sulfhydryl group.
- the hemoglobin is released from cells in a sample and is contacted with a first agent, labeled with a first detectable marker, that binds hemoglobin and with a second agent that is labeled with a second detectable marker, that binds only glycated hemoglobin.
- the first detectable marker is a first fluorophore that fluoresces upon exposure to light of a first wavelength and the second detectable marker is a second fluorophore that fluoresces upon exposure to light of a second wavelength.
- the detectably labeled hemoglobin, including the detectably labeled glycated hemoglobin is then immobilized at the same region on a solid support.
- the signals from the first detectable marker and the second detectable marker immobilized on the solid support are measured by exposing the region of the chromatographic strip to which hemoglobin, including glycated hemoglobin, is immobilized to light of the first and second wavelengths.
- the percentage of glycated hemoglobin in the sample is determined based on the signals from the first detectable marker and the second detectable marker.
- detectable marker and the second detectable marker are measured simultaneously by simultaneously exposing the region of the solid support to which hemoglobin, including glycated hemoglobin, is immobilized to light of the first and second wavelengths.
- the invention provides a glycated hemoglobin coupled to both an antibody that recognizes hemoglobin labeled with a first detectable marker and to a boronic acid or a derivative thereof labeled with a second detectable marker.
- the boronic acid or derivative thereof is directly coupled to the detectable marker and can be detected by any means described above without the use of another agent, e.g., an antibody specific for either the boronic acid/boronic acid derivative or the bound .GHb.
- the first and second detectable markers may be selected from any of the categories and examples of markers discussed above.
- the boronic acid, or derivative thereof may be any suitable compound, for example, any of those described above.
- the invention provides a system for quantitatively determining the percentage of glycated hemoglobin in a blood sample.
- the system can be any device that allows hemoglobin and glycated hemoglobin to be localized such that the relative quantities of the two can be determined.
- the system may be a test strip, e.g., a lateral flow test strip that supports uni-directional or bi-directional the flow of fluid across the test strip.
- the system is a dipstick that is dipped into the sample comprising hemoglobin released from RBCs. In the dipstick embodiment, it would be appreciated that the lysed sample is pre-mixed with the first and second detectably labeled agents.
- the solid support is a multi-well plastic plate used in ELISA assays, or a microcapillary system.
- the system may be a microfluidics device.
- microfluidics devices may employ chambers in which the capture agent that binds total Hb is immobilized.
- Microfluidics methods and devices are described, for example, in Martinez et al., "Three-Dimensional Microfluidic Devices Fabricated in Layered Paper and Tape," PNAS, Vol. 105, No. 50 (Dec. 16, 2008) 19606-19611; P. K. Sorger, "Microfluidics Closes in on Point-of-Care Assays," Nature Biotechnology, Vol. 26, No. 12 (Dec. 2008) 1345-1378; and B. Grant, "The 3 Cent Microfluidics Chip,” The Philosoph (December 8, 2008), all of which are incorporated herein by reference in their entirety.
- the system is a test strip.
- the test strip comprises a chromatographic strip, a coating on a portion of the chromatographic strip that comprises an Attorney Docket No.: RLA0007-401 PC
- immobilized capture agent that binds to hemoglobin in a sample, a region on the chromatographic strip to which sample is added; and a region on the chromatographic strip that comprises a first agent, labeled with a first detectable marker, that binds hemoglobin, and a second agent, labeled with a second detectable marker, that binds only glycated hemoglobin.
- the test strip is configured such that sample that is added to the test strip flows across the region comprising the first and second detectably labeled agents before reaching the region that comprises the capture agent.
- the region on the chromatographic strip that comprises the first detectably labeled agent and the second detectably labeled agent can be located either at the region to which the sample is added or in between the region to which the sample is added and the region comprising the capture agent.
- the first and second agents, the capture agent as well as the first and second detectable markers may be any agent or marker as previously described.
- the capture agent is immobilized in a capture zone.
- the capture zone may be made of any size or shape. It could be a band (e.g., a "test band"), i.e., in the shape of a rectangle that spans the width, partially or completely, of the test strip in a direction perpendicular to the flow of the fluid, or it could be a "spot" that is approximately circular or oval.
- the chromatographic strip may comprise more than one capture zone that capture hemoglobin, including glycated hemoglobin such that glycated and unglycated hemoglobin are co-localized.
- the chromatographic strip comprises at least two capture zones, a first capture zone comprising a first capture agent that immobilizes glycated hemoglobin and a second capture zone comprising a second capture agent that immobilizes unglycated hemoglobin.
- the signal from the first detectable marker bound to hemoglobin would be measured from both the first and the second capture zones, whereas the signal from the second detectable marker bound only to glycated hemoglobin would be measured only from the first capture zone.
- a detectably-labeled agent that specifically binds hemoglobin e.g., an antibody
- a detectably-labeled agent that specifically binds hemoglobin e.g., an antibody
- a test strip that comprises two capture zones, a first capture zone with a capture agent specific for glycated hemoglobin (such as an anti-GHb antibody or a boronic acid or a derivative thereof), and a second capture zone that binds Hb, such that the sample is contacted with the first capture zone before it is Attorney Docket No.: RLA0007-401 PC
- the percentage of glycated hemoglobin in the sample can be determined based on the signals measured from the different positions of the test strip.
- a first capture zone comprising a first capture agent that binds and immobilizes GHb that is located closer to the region of the test strip to which sample is added as compared to a second capture zone comprising a second capture agent that binds and immobilizes Hb is also within the scope of the invention.
- the test strip comprises a conjugate pad that comprises the first and second detectably labeled agents.
- the test strip may comprise a sample pad to which the sample is added.
- the sample pad may be located generally above the conjugate pad such that sample that is added to the sample pad flows to the conjugate pad and from the conjugate pad onto the chromatographic strip.
- the conjugate pad may be located on the chromatographic strip in between the sample pad and the region(s) comprising the immobilized capture agent (the capture zone(s)).
- the sample pad acts like a reservoir and allows fluid, e.g., the sample or buffer, to be released slowly and constantly on to the conjugate pad and the chromatographic strip. This not only ensures even flow of sample across the test strip, but also provides sufficient time for the hemoglobin and glycated hemoglobin present in the sample to bind to the first and second detectably labeled agents, respectively, that are present in the conjugate pad.
- the retention time of the sample pad varies according to the size of the sample pad, the size of the test strip and the volume of sample added to the sample pad.
- the sample pad can release the sample over a period of about 60 minutes, about 50 minutes, about 40 minutes, about 35 minutes, about 30 minutes, about 25 minutes, about 20 minutes, about 15 minutes, about 10 minutes, about 5 minutes, about 3 minutes, about 2 minutes, or about 1 minute.
- the sample pad can hold and release buffer and sample for more than 20 minutes.
- a method in which hemoglobin released from RBCs is contacted with a detectably-labeled agent that specifically binds hemoglobin e.g., an anti-Hb antibody
- a detectably-labeled agent that specifically binds hemoglobin e.g., an anti-Hb antibody
- immobilized on a test strip that comprises two capture zones, a first capture zone with a capture agent specific for glycated hemoglobin (such as an anti-GHb antibody or a boronic acid or a derivative thereof), and a second capture zone that binds Hb, such that the sample is contacted with the first capture zone before it is contacted with the second capture zone
- a detectably-labeled agent that specifically binds hemoglobin e.g., an anti-Hb antibody
- the percentage of glycated hemoglobin in the sample can be determined based on the signals measured from the different positions of the test strip.
- alternate embodiments of the test strip that comprise two capture zones, a first capture zone comprising a first capture agent that binds and immobilizes GHb that is located closer to the region of the test strip to which sample is added as compared to a second capture zone comprising a second capture agent that binds and immobilizes Hb is also within the scope of the invention.
- test strips/systems and methods have been described in some detail here by way of illustration and example, such illustration and example is for purposes of clarity of understanding only. It will be readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2799996A CA2799996C (en) | 2009-05-20 | 2010-05-20 | Systems and methods for determining the percentage of glycated hemoglobin |
CN201080032364.8A CN102640002B (en) | 2009-05-20 | 2010-05-20 | Detect the system and method for glycosylated hemoglobin number percent |
EP10778412.6A EP2433140B1 (en) | 2009-05-20 | 2010-05-20 | Systems and methods for determining the percentage of glycated hemoglobin |
AU2010249486A AU2010249486B2 (en) | 2009-05-20 | 2010-05-20 | Systems and methods for determining the percentage of glycated hemoglobin |
ES10778412.6T ES2536112T3 (en) | 2009-05-20 | 2010-05-20 | Systems and methods to determine the percentage of glycohemoglobin |
HK13101834.3A HK1174688A1 (en) | 2009-05-20 | 2013-02-08 | Systems and methods for determining the percentage of glycated hemoglobin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18007509P | 2009-05-20 | 2009-05-20 | |
US61/180,075 | 2009-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010135574A2 true WO2010135574A2 (en) | 2010-11-25 |
WO2010135574A3 WO2010135574A3 (en) | 2011-04-21 |
Family
ID=43126774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/035648 WO2010135574A2 (en) | 2009-05-20 | 2010-05-20 | Systems and methods for determining the percentage of glycated hemoglobin |
Country Status (8)
Country | Link |
---|---|
US (2) | US8703494B2 (en) |
EP (1) | EP2433140B1 (en) |
CN (1) | CN102640002B (en) |
AU (1) | AU2010249486B2 (en) |
CA (1) | CA2799996C (en) |
ES (1) | ES2536112T3 (en) |
HK (1) | HK1174688A1 (en) |
WO (1) | WO2010135574A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014033258A1 (en) * | 2012-08-31 | 2014-03-06 | Axis-Shield Asa | Glycated haemoglobin assay method |
WO2014147395A1 (en) * | 2013-03-20 | 2014-09-25 | The University Of Bath | Materials and methods for analysing glycation |
WO2016040870A1 (en) * | 2014-09-12 | 2016-03-17 | Beckman Coulter, Inc. | Systems and methods to determine the age of cells |
WO2018009143A1 (en) * | 2016-07-07 | 2018-01-11 | Cell Id Pte Ltd | Haemoglobin test kit |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2947632B1 (en) * | 2009-07-01 | 2011-11-11 | Sebia Sa | ANALYSIS AND DETERMINATION OF GLYCATED HEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS AND KITS FOR CAPILLARY ELECTROPHORESIS |
KR20120051133A (en) * | 2010-11-12 | 2012-05-22 | 삼성전자주식회사 | Microfluidic device and hemoglobin measuring method thereof |
CN102435753A (en) * | 2011-08-31 | 2012-05-02 | 内蒙古科慧生物科技有限责任公司 | Quantitative determination kit and detection method for glycosylated hemoglobin (HbAlc) |
CN102998463A (en) * | 2012-11-29 | 2013-03-27 | 英科新创(厦门)科技有限公司 | Method for measuring glycosylated hemoglobin and kit |
CN104345149A (en) * | 2013-07-26 | 2015-02-11 | 深圳市艾瑞生物科技有限公司 | Immunochromatography test strip for detecting glycosylated hemoglubin and preparation method thereof |
CN104422764A (en) * | 2013-09-04 | 2015-03-18 | 深圳市艾瑞生物科技有限公司 | Glycoprotein-type tumor marker immunochromatographic test strip as well as preparation method and application thereof |
RU2698311C2 (en) * | 2014-03-20 | 2019-08-26 | Байо-Ред Лабораториз, Инк. | Analysis for glycated proteins |
JP5792859B1 (en) * | 2014-04-04 | 2015-10-14 | 田中貴金属工業株式会社 | Immunochromatographic analysis method |
DK3397971T3 (en) * | 2015-12-30 | 2021-09-20 | W Health L P | Method for determining the amount of an HBA1C in a blood sample |
CN107490680A (en) * | 2016-06-09 | 2017-12-19 | 常州博闻迪医药科技有限公司 | A kind of Blood glycated haemoglobin enzyme-linked immune detection method |
CN107656074A (en) * | 2017-09-07 | 2018-02-02 | 基蛋生物科技股份有限公司 | A kind of kit that glycosylated hemoglobin is detected using Two Colour Fluorescence immunochromatography technique |
CN110346580A (en) * | 2018-04-04 | 2019-10-18 | 南京东纳生物科技有限公司 | A kind of glycosylated hemoglobin fluorescence is affine immunochromatographytest test kit and detection method |
US20200284807A1 (en) * | 2019-03-05 | 2020-09-10 | Victor Manneh | Saturation binding ratiometric assay |
CN113825984A (en) * | 2019-05-20 | 2021-12-21 | 美国西门子医学诊断股份有限公司 | Method for detecting abnormal results in immunoassays caused by incomplete delivery of polyhapten reagents |
EP3990918A4 (en) * | 2019-06-27 | 2023-07-19 | Case Western Reserve University | Compositions and methods for blood and anemia detection |
CN110967488B (en) * | 2019-12-20 | 2023-04-07 | 深圳优迪生物技术有限公司 | Test strip, kit and method for measuring glycosylated hemoglobin |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4206932A1 (en) * | 1992-03-05 | 1993-09-09 | Boehringer Mannheim Gmbh | IMMUNOLOGICAL METHOD FOR DETERMINING A HAEMOGLOBIN DERIVATIVE |
JP3150857B2 (en) * | 1994-10-19 | 2001-03-26 | 富士写真フイルム株式会社 | Analysis element and method for measuring glycohemoglobin content ratio |
US6162645A (en) * | 1997-03-13 | 2000-12-19 | Abbott Laboratories | Determination of % glycated hemoglobin |
US6394952B1 (en) * | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
DE19843094A1 (en) * | 1998-09-21 | 2000-03-23 | Roche Diagnostics Gmbh | Method for the determination of glycated hemoglobin |
CN1327159A (en) * | 2000-06-05 | 2001-12-19 | 刘永详 | Immune analysis method, reagent and device for detecting saccharified protein |
CN1489693B (en) * | 2001-01-31 | 2010-04-28 | 斯克利普斯实验室 | Method and devices for quantitation of glycated protein |
US6677158B2 (en) * | 2001-03-14 | 2004-01-13 | Exocell Inc. | Method for measurement of glycated hemoglobin by a rapid strip test procedure |
AU2003291250A1 (en) * | 2002-11-05 | 2004-06-07 | Therasense, Inc. | Assay device, system and method |
US20050014249A1 (en) * | 2003-02-21 | 2005-01-20 | Norbert Staimer | Chromatographic analysis on optical bio-discs and methods relating thereto |
US20050037484A1 (en) * | 2003-04-23 | 2005-02-17 | Norbert Staimer | Optical bio-discs including spiral fluidic circuits for performing assays |
ATE509275T1 (en) * | 2003-09-23 | 2011-05-15 | Epinex Diagnostic Inc | RAPID TEST FOR GLYCATED ALBUMIN |
CA2514010A1 (en) * | 2004-08-03 | 2006-02-03 | Axis-Shield Diagnostics Limited | Assay |
KR100662021B1 (en) * | 2005-12-30 | 2006-12-27 | 주식회사 인포피아 | Bio cartridge |
US8309313B2 (en) * | 2006-03-06 | 2012-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycated peptides and methods of use |
ES2404059T3 (en) * | 2006-07-25 | 2013-05-23 | General Atomics | Procedures to analyze the percentage of glycated hemoglobin |
-
2010
- 2010-05-20 CN CN201080032364.8A patent/CN102640002B/en active Active
- 2010-05-20 WO PCT/US2010/035648 patent/WO2010135574A2/en active Application Filing
- 2010-05-20 ES ES10778412.6T patent/ES2536112T3/en active Active
- 2010-05-20 EP EP10778412.6A patent/EP2433140B1/en active Active
- 2010-05-20 US US12/784,280 patent/US8703494B2/en active Active
- 2010-05-20 AU AU2010249486A patent/AU2010249486B2/en active Active
- 2010-05-20 CA CA2799996A patent/CA2799996C/en active Active
-
2013
- 2013-02-08 HK HK13101834.3A patent/HK1174688A1/en unknown
-
2014
- 2014-03-04 US US14/196,384 patent/US9459262B2/en active Active
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2433140A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014033258A1 (en) * | 2012-08-31 | 2014-03-06 | Axis-Shield Asa | Glycated haemoglobin assay method |
WO2014147395A1 (en) * | 2013-03-20 | 2014-09-25 | The University Of Bath | Materials and methods for analysing glycation |
WO2016040870A1 (en) * | 2014-09-12 | 2016-03-17 | Beckman Coulter, Inc. | Systems and methods to determine the age of cells |
US10739357B2 (en) | 2014-09-12 | 2020-08-11 | Beckman Coulter, Inc. | Systems and methods to determine the age of cells |
WO2018009143A1 (en) * | 2016-07-07 | 2018-01-11 | Cell Id Pte Ltd | Haemoglobin test kit |
CN109564228A (en) * | 2016-07-07 | 2019-04-02 | 源鉴定私人有限公司 | Hemoglobin detection kit |
Also Published As
Publication number | Publication date |
---|---|
CA2799996A1 (en) | 2010-11-25 |
AU2010249486B2 (en) | 2016-02-25 |
EP2433140A2 (en) | 2012-03-28 |
WO2010135574A3 (en) | 2011-04-21 |
US20140186862A1 (en) | 2014-07-03 |
HK1174688A1 (en) | 2013-06-14 |
CN102640002B (en) | 2015-08-05 |
US9459262B2 (en) | 2016-10-04 |
CN102640002A (en) | 2012-08-15 |
US20110070658A1 (en) | 2011-03-24 |
ES2536112T3 (en) | 2015-05-20 |
AU2010249486A1 (en) | 2012-01-19 |
EP2433140B1 (en) | 2015-02-11 |
EP2433140A4 (en) | 2012-10-31 |
US8703494B2 (en) | 2014-04-22 |
CA2799996C (en) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2799996C (en) | Systems and methods for determining the percentage of glycated hemoglobin | |
US8093057B2 (en) | System for quantitative measurement of glycohemoglobin and method for measuring glycohemoglobin | |
EP1664783B1 (en) | Rapid test for glycated albumin | |
US9128085B2 (en) | Rapid test for glycated albumin in blood | |
US5674699A (en) | Two-phase optical assay | |
US20040018576A1 (en) | Bence Jones protein testing cassette | |
KR100910982B1 (en) | System for the quantitative measurement of glycohemoglobin and a method for measuring the content of glycohemoglobin using the same | |
US20140170766A1 (en) | Aptamer Based Point-of-Care Test for Glycated Albumin | |
JP2007528005A (en) | Combined system of body fluid sample measuring instrument and cartridge | |
KR101271022B1 (en) | Membrane Biosensor Attached with Porous Film and Method for Detecting Immune Reaction or Enzyme Reaction Using the Same | |
US20060270060A1 (en) | Rapid test for glycated albumin in saliva | |
EP3120147B1 (en) | Glycated protein assay | |
KR20160120675A (en) | Rapid Quantitative Diagnostic Kit | |
JP2004532388A (en) | Methods and devices for quantification of glycosylated proteins | |
KR20020066792A (en) | Rapid Diagnosis Kit for Diabetes Using Immunochoromatography and Detection Method | |
KR20040018893A (en) | Rapid Diagnosis Kit and Detection Method for Hemoglobin A1c Using Immunochoromatography | |
JP4600787B2 (en) | Chromatographic device | |
CN109540846B (en) | Method for measuring glycated protein | |
KR20150111391A (en) | Immunochromatography Analysis Device | |
JPH0783921A (en) | Method for measuring saccharification protein | |
JPH0658936A (en) | Method for measuring saccharifying protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080032364.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10778412 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5027/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010249486 Country of ref document: AU Ref document number: 2010778412 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010249486 Country of ref document: AU Date of ref document: 20100520 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2799996 Country of ref document: CA |